Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG GENES KEGG PATHWAY KEGG DRUG DrugBank 指定難病告示番号
1 CHRM3 11件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D00646 Tolterodine 2件: 17, 53
2 COMT 4件: Steroid hormone biosynthesis, Tyrosine metabolism, Metabolic pathways, Dopaminergic synapse D00781 Entacapone 2件: 6, 17
3 ADRA1D 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D01277 Droxidopa 5件: 5, 6, 17, 169, 170
4 ADRA1D 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08220 Midodrine 3件: 6, 17, 58
5 ADRA1D 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08449 Pseudoephedrine 1件: 17
6 ADRA1B 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D01277 Droxidopa 5件: 5, 6, 17, 169, 170
7 ADRA1B 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08220 Midodrine 3件: 6, 17, 58
8 ADRA1B 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08449 Pseudoephedrine 1件: 17
9 ADRA1A 7件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D01277 Droxidopa 5件: 5, 6, 17, 169, 170
10 ADRA1A 7件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08220 Midodrine 3件: 6, 17, 58
11 ADRA1A 7件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D08449 Pseudoephedrine 1件: 17
12 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01277 Droxidopa 5件: 5, 6, 17, 169, 170
13 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08449 Pseudoephedrine 1件: 17
14 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01277 Droxidopa 5件: 5, 6, 17, 169, 170
15 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08449 Pseudoephedrine 1件: 17
16 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01277 Droxidopa 5件: 5, 6, 17, 169, 170
17 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08449 Pseudoephedrine 1件: 17
18 ADRB1 11件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D01277 Droxidopa 5件: 5, 6, 17, 169, 170
19 ADRB1 11件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D02358 Metoprolol 6件: 17, 57, 58, 113, 193, 226
20 ADRB1 11件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D05127 Nebivolol 4件: 17, 85, 113, 167
21 ADRB1 11件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D08449 Pseudoephedrine 1件: 17
22 ADRB2 9件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D01277 Droxidopa 5件: 5, 6, 17, 169, 170
23 ADRB2 9件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D08449 Pseudoephedrine 1件: 17
24 ADRB3 8件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D01277 Droxidopa 5件: 5, 6, 17, 169, 170
25 ADRB3 8件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D08449 Pseudoephedrine 1件: 17
26 ACE 6件: Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy D00251 Captopril 8件: 6, 17, 46, 86, 96, 97, 107, 271
27 DDC 9件: Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Cocaine addiction, Amphetamine addiction, Alcoholism D00558 Carbidopa 7件: 6, 13, 17, 90, 140, 164, 201
28 DRD1 10件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Morphine addiction, Alcoholism D00059 Levodopa 6件: 6, 17, 90, 140, 164, 201
29 DRD2 8件: Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D00059 Levodopa 6件: 6, 17, 90, 140, 164, 201
30 DRD2 8件: Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D01745 Domperidone 5件: 6, 13, 17, 51, 230
31 DRD2 8件: Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D07868 Domperidone 5件: 6, 13, 17, 51, 230
32 DRD3 2件: Neuroactive ligand-receptor interaction, Dopaminergic synapse D00059 Levodopa 6件: 6, 17, 90, 140, 164, 201
33 DRD4 2件: Neuroactive ligand-receptor interaction, Dopaminergic synapse D00059 Levodopa 6件: 6, 17, 90, 140, 164, 201
34 DRD5 4件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Dopaminergic synapse D00059 Levodopa 6件: 6, 17, 90, 140, 164, 201
35 AGTR1 16件: Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D00150 Angiotensin II 7件: 17, 19, 46, 66, 86, 222, 224
36 AGTR1 16件: Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D02014 Angiotensin II 7件: 17, 19, 46, 66, 86, 222, 224
37 AGTR1 16件: Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D08146 Losartan 17件: 17, 19, 36, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299
38 AGTR2 3件: Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Renin-angiotensin system D00150 Angiotensin II 7件: 17, 19, 46, 66, 86, 222, 224
39 AGTR2 3件: Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Renin-angiotensin system D02014 Angiotensin II 7件: 17, 19, 46, 66, 86, 222, 224
40 FDPS 4件: Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection D01968 Zoledronic acid 13件: 5, 6, 13, 17, 46, 65, 93, 95, 96, 270, 274, 299, 333
41 FDPS 4件: Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection D08689 Zoledronic acid 13件: 5, 6, 13, 17, 46, 65, 93, 95, 96, 270, 274, 299, 333
42 MTOR 51件: EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, HIF-1 signaling pathway, Phospholipase D signaling pathway, Autophagy - other, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Cellular senescence, Apelin signaling pathway, Neutrophil extracellular trap formation, JAK-STAT signaling pathway, Th17 cell differentiation, Thermogenesis, Insulin signaling pathway, Thyroid hormone signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Growth hormone synthesis, secretion and action, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Shigellosis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Colorectal cancer, Pancreatic cancer, Glioma, Prostate cancer, Acute myeloid leukemia, Breast cancer, Hepatocellular carcinoma, Gastric cancer, Central carbon metabolism in cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Diabetic cardiomyopathy D00753 Sirolimus 40件: 2, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331
43 GABRA1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00697 Flumazenil 5件: 6, 13, 17, 18, 206
44 GABRA2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00697 Flumazenil 5件: 6, 13, 17, 18, 206
45 GABRA3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00697 Flumazenil 5件: 6, 13, 17, 18, 206
46 GABRA4 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00697 Flumazenil 5件: 6, 13, 17, 18, 206
47 GABRA5 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00697 Flumazenil 5件: 6, 13, 17, 18, 206
48 GABRA6 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00697 Flumazenil 5件: 6, 13, 17, 18, 206
49 GABRB1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil 5件: 6, 13, 17, 18, 206
50 GABRB2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil 5件: 6, 13, 17, 18, 206
51 GABRB3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil 5件: 6, 13, 17, 18, 206
52 GABRD 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil 5件: 6, 13, 17, 18, 206
53 GABRE 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil 5件: 6, 13, 17, 18, 206
54 GABRG1 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil 5件: 6, 13, 17, 18, 206
55 GABRG2 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil 5件: 6, 13, 17, 18, 206
56 GABRG3 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil 5件: 6, 13, 17, 18, 206
57 GABRP 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil 5件: 6, 13, 17, 18, 206
58 GLP1R 3件: cAMP signaling pathway, Neuroactive ligand-receptor interaction, Insulin secretion D04121 Exenatide 6件: 6, 17, 72, 78, 193, 233
59 GRIA1 14件: cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
60 GRIA2 15件: cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
61 GRIA3 13件: cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction, Transcriptional misregulation in cancer D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
62 GRIA4 10件: cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
63 GRIK1 2件: Neuroactive ligand-receptor interaction, Glutamatergic synapse D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
64 GRIK2 2件: Neuroactive ligand-receptor interaction, Glutamatergic synapse D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
65 GRIK3 2件: Neuroactive ligand-receptor interaction, Glutamatergic synapse D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
66 GRIK4 2件: Neuroactive ligand-receptor interaction, Glutamatergic synapse D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
67 GRIK5 2件: Neuroactive ligand-receptor interaction, Glutamatergic synapse D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
68 GRIN1 18件: Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
69 GRIN2A 19件: Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
70 GRIN2B 19件: Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
71 GRIN2C 15件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
72 GRIN2D 15件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
73 MAOB 14件: Glycine, serine and threonine metabolism, Arginine and proline metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Alcoholism D08469 Rasagiline 6件: 2, 5, 6, 17, 58, 66
74 MAOB 14件: Glycine, serine and threonine metabolism, Arginine and proline metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Alcoholism D10158 Safinamide 2件: 6, 17
75 MAOB 14件: Glycine, serine and threonine metabolism, Arginine and proline metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Alcoholism D10829 Rasagiline 6件: 2, 5, 6, 17, 58, 66
76 NR3C2 1件: Aldosterone-regulated sodium reabsorption D07967 Fludrocortisone 2件: 17, 81
77 MPO 5件: Drug metabolism - other enzymes, Phagosome, Neutrophil extracellular trap formation, Transcriptional misregulation in cancer, Acute myeloid leukemia D11684 Verdiperstat 3件: 2, 17, 127
78 GABRQ 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil 5件: 6, 13, 17, 18, 206
79 SLC6A2 1件: Synaptic vesicle cycle D07473 Atomoxetine 1件: 17
80 SLC6A2 1件: Synaptic vesicle cycle D11688 Ampreloxetine 1件: 17
81 SLC6A4 2件: Synaptic vesicle cycle, Serotonergic synapse D00326 Fluoxetine 6件: 13, 17, 78, 86, 179, 206
82 SLC6A4 2件: Synaptic vesicle cycle, Serotonergic synapse D11688 Ampreloxetine 2件: 6, 17
83 SNAP25 2件: Synaptic vesicle cycle, Insulin secretion D00783 Botulinum toxin type A 14件: 2, 5, 6, 7, 13, 15, 17, 36, 47, 51, 70, 113, 149, 226